Latest Reoviridae Stories
CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the Cancer...
CALGARY, May 10, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that all nominees listed in the management information circular dated April 4, 2013 were elected as directors at its 2013 Annual and Special Meeting of Shareholders, held on Thursday, May 9th, 2013. On a vote by ballot, the following nine nominees proposed by management were elected as Directors of Oncolytics to serve until the Company`s next Annual Meeting of Shareholders or until...
CALGARY, Feb. 20, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX: ONC, NASDAQ: ONCY) today announced the appointment of Dr. Jeremy Grushcow to the role of General Counsel. Dr. Grushcow has more than ten years' experience in the legal profession representing public and private entities, as well as venture capital and private equity firms in the acquisition, financing, development, operation and sale of pharmaceutical and life sciences companies in...
CALGARY, Nov. 12, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced the appointment of Mr. Kirk Look to the role of Chief Financial Officer. Mr. Look has served as Oncolytics' Controller since 2003 and has been the Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, Mr. Look held progressively senior audit roles with Ernst & Young LLP in both North and South America...
CALGARY, Nov. 9, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced three poster presentations covering expanded results from: a Phase II clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumours (REO 016), a Phase II clinical trial using intravenous administration of REOLYSIN( )in combination with...
A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.By the age of five, most people have been exposed to the virus, called reovirus. For some, it can trigger brief episodes of coughing or...
CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent, # 7,803,385 entitled "Reoviruses Having Modified Sequences." The patent claims cover methods for making and using modified reoviruses, and pharmaceutical compositions that include modified reoviruses. "This composition of matter patent covers the reovirus variant that Oncolytics is using in its clinical trials with patent protection...
Latest Reoviridae Reference Libraries
Reoviridae is a family of viruses that can affect the gastrointestinal system (such as Rotavirus) and respiratory tract. These viruses have genomes consisting of segmented, double-stranded RNA. The name is derived from respiratory enteric orphan viruses. Orphan virus means that a virus that is not associated with any known disease. Reovirus infection occurs often in humans, but cases are generally mild or sub-clinical. The virus can be detected in feces, and also in pharyngeal or nasal...
Bluetongue disease is a viral disease that is non-contagious, non-zoonotic, and insect-borne. It is mainly found in sheep and less commonly in cattle, goats, buffalo, deer, dromedaries, and antelope. It is not transmissible to humans. The virus is pathogenic, part of the genus Orbivirus, and is a member of the Reoviridae family. With 24 serotypes the virus can cause serious disease in livestock. Due to its seriousness BTV has received extensive research for the last three decades and is...
